Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Amarillo Biosciences Signs Deal with CytoPharm of Taiwan

publication date: Mar 25, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Amarillo Biosciences, Inc. has entered a second license and supply agreement with CytoPharm, Inc. of Taiwan for Amarillo Biosciences’ low-dose interferon. Under this agreement, CytoPharma will conduct tests to support the use of low-dose interferon in animals (swine, poultry, cattle) to treat or prevent animal diseases. CytoPharm will seek approval of the drug in Taiwan and China. CytoPharm is already conducting a Phase II clinical trial to test whether low-dose interferon can prevent relapse in hepatitis C patients. More details...

Stock Symbol: (OTCBB: AMAR)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...